摘要
目的建立重组人尿激酶原(rhPro-UK)药物利用评价(DUE)标准,为临床合理应用rhPro-UK提供参考。方法以rhPro-UK说明书为基础,参考相关指南、专家共识、权威文献,采用专家咨询法建立rhPro-UK的DUE标准细则。采用回顾性方法,对锡林郭勒盟中心医院2019年1月—2022年5月使用rhPro-UK的住院患者病历进行合理性评价,基于临床结局评价其有效性,基于不良反应发生率和严重程度评价其安全性。结果共纳入230份病历,4例完全符合评价标准(用药指征、用药过程、用药结果),占比1.74%;226例(98.26%)患者用药不合理,主要表现在用药指征、用药过程(给药方式、给药剂量)两方面。221例患者治疗有效,总有效率96.09%;139例患者发生不良反应,发生率60.43%。结论我院临床使用rhPro-UK在用药指征和用药过程存在不合理现象,建立rhPro-UK的DUE标准细则可为规范rhPro-UK临床应用提供参考,促进其合理使用。
Objective To establish the drug use evaluation(DUE) criteria of recombinant human prourokinase(rhPro-UK),and to provide reference for the rational clinical application of rhPro-UK.Methods Based on the drug instructions of rhPro-UK,DUE standard rules were established by referring to relevant guidelines,expert consensus,authoritative literature and expert consultation.The medical records of hospitalized patients treated with rhPro-UK from January 2019 to May 2022 in Xilin Gol League Central Hospital were evaluated by retrospective investigation.The effectiveness of rhPro-UK was evaluated based on clinical outcome,and its safety was evaluated based on the incidence and severity of adverse reactions.Results A total of 230 cases were included,and 4 cases fully met the evaluation criteria(medication indication,medication process,medication results),accounting for 1.74%.There were 226 patients(98.26%) with irrational drug use,mainly manifested in two aspects of drug indication and drug process( administration mode and dosage).Treatment was effective in 221 patients,with an overall effective rate of 96.09%;139patients experienced adverse reactions,with an incidence rate of 60.43%.Conclusion The clinical use of rhPro-UK in our hospital is irrational in the indication of medication and the process of medication,and the establishment of the DUE standard rules of rhPro-UK can provide a reference to standardize the clinical application of rhPro-UK and promote its rational use.
作者
庄志鹤
秦芹
蔡慧雅
马天宇
王润秋
向倩
张进华
ZHUANG Zhihe;QIN Qin;CAI Huiya;MA Tianyu;WANG Runqiu;XIANG Qian;ZHANG Jinhua(Department of Pharmacy,Xilin Gol League Central Hospital,Xilin Gol 026000,Inner Mongolia Autonomous Region,China;Department of Pharmacy,Luxian People's Hospital,Luzhou 646000,Sichuan Province,China;Department of Pharmacy,Zhangzhou Second Hospital,Zhangzhou 363199,Fujian Province,China;Department of Clinical Nutrition,Xilin Gol League Central Hospital,Xilin Gol 026000,Inner Mongolia Autonomous Region,China;Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Department of Pharmacy,Fujian Maternity and Child Health Care Hospital,Fuzhou 350001,China)
出处
《药物流行病学杂志》
CAS
2024年第4期371-380,共10页
Chinese Journal of Pharmacoepidemiology
基金
内蒙古公立医院科研联合基金科技项目(2023GLLH0441)。
关键词
重组人尿激酶原
药物利用评价
标准细则
合理用药
药品不良反应
Recombinant human prourokinase
Drug use evaluation
Standard rules
Rational drug use
Adverse drug reaction
